Shares of Pulse Biosciences Inc. (NASDAQ: PLSE) surged 6.10% on October 30, 2024, following the company's release of its third-quarter 2024 financial results and a series of positive business updates.
The bioelectric medicine company reported a net loss of $12.7 million for the third quarter, but investors seemed to focus on the progress made in the development of its novel Nanosecond Pulsed Field Ablation (nsPFA) technology and the potential it holds across various applications.
One of the key highlights was the appointment of Dr. David Kenigsberg as Chief Medical Officer of Electrophysiology and the addition of Dr. Andrea Natale as a medical advisor. Both renowned physicians will contribute their expertise in supporting the clinical development of Pulse Biosciences' nano-PFA 360 Cardiac Catheter for the treatment of atrial fibrillation.
Furthermore, the company provided updates on the progress of clinical trials for its nsPFA technology. Pulse Biosciences expects to commence pivotal trials in the U.S. for its Percutaneous Electrode System for benign thyroid nodules, its Cardiac Surgical System for atrial fibrillation treatment, and its 360 Cardiac Catheter, all in mid-2025. These milestones are seen as crucial steps towards potential commercialization of the company's innovative technology.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。